Corticosteroids and Hemoglobin A1C Levels in Diabetic Patients With COPD Exacerbation

Completed

• Conditions: Diabetes; Chronic Obstructive Pulmonary Disease

• Registration Number: NCT01798420
• Lead Sponsor: The Nazareth Hospital, Israel

Brief Summary

Corticosteroid treatment in diabetic patients admitted for COPD exacerbation are expected to significantly increase hemoglobin A1C levels

Detailed Description

HbA1C levels were evaluated in diabetic patients with COPD exacerbation on admission to the hospital and 3-months later. Demographic, clinical, laboratory variables and total steroid dose were documented. Age- and sex-matched group of diabetic patients with COPD who were admitted for other reasons, were asked to participate as a control group. Mann-Whitney and Chi square/Fischer's exact tests were used to compare between the parameters of the two groups. Wilcoxon signed rank test was used to compare between HbA1C levels at baseline and 3 months later. Multi-variate linear regression analysis was used to find predictors for increase in HbA1C levels in the patients' group.

Study Timeline

• Study Start: 2012-04
• Primary Completion: 2012-09
• Study Completion: 2012-10
• Status Verified: 2013-02
• Study First Submitted: 2013-02-21
• Study First Submitted QC: 2013-02-22
• Last Update Submitted: 2013-02-22
• Study First Posted: 2013-02-25
• Last Update Posted: 2013-02-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

• Diabetic patients with COPD exacerbation

Exclusion Criteria

• Patients treated with steroids during the previous 3 months

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hemoglobin A1C LEVEL	3 MONTHS

Secondary Outcome Measures

Name	Time	Method
Glucose levels	3 months

Trial Locations

Locations (1)

Department of medicine; 🇮🇱 Nzareth, Nazareth, Israel